TherapeuticsMD Inc

For the period ended Mar 31, 2024. Filed May 10, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 10, 2024

TXMD$1.69-2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except per share data)

	March 31, 2024	December 31, 2023
(Unaudited)
Assets:
Current assets:
Cash and cash equivalents	$4,338	$4,327
Royalty receivable, current portion	3,222	3,090
Prepaid and other current assets	3,869	4,035
Current assets of discontinued operations	94	344
Total current assets	11,523	11,796
License rights and other intangible assets, net	5,965	6,098
Right of use assets	6,687	6,873
Royalty receivable, long term	17,855	18,484
Other non-current assets	58	58
Total assets	$42,088	$43,309
Liabilities and stockholders’ equity:
Current liabilities:
Accounts payable	$139	$27
Accrued expenses and other current liabilities	2,720	3,133
Current liabilities of discontinued operations	3,609	3,694
Total current liabilities	6,468	6,854
Operating lease liabilities	6,319	6,532
Other non-current liabilities	637	636
Total liabilities	13,424	14,022
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, par value $0.001; 32,000 shares authorized, 11,532 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	11	11
Additional paid-in capital	979,028	978,917
Accumulated deficit	(950,375)	(949,641)
Total stockholders’ equity	28,664	29,287
Total liabilities and stockholders’ equity	$42,088	$43,309

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.